Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis

By
Mohamed M. Khamis
Nehemias Antonio Guevara Rodriguez
Ranju Kunwor
May 29, 2026

Frontiers In Hematology

Overview

This systematic review and meta-analysis evaluates the efficacy of reduced-intensity all-trans retinoic acid plus arsenic trioxide (ATRA+ATO) versus intensive chemotherapy in high-risk acute promyelocytic leukemia (APL). Findings indicate that reduced-intensity induction achieves comparable complete remission rates, lower early mortality, and superior event-free survival.

Background

Incorporate statistics on early mortality rates for high-risk APL to provide context.

Data Highlights

Outcome	Reduced-Intensity	Intensive	p-value
Complete Remission (CR)	92.3% (95%CI = 85.9–95.9%)	89.3% (82.6%–93.6%)	0.35
Early Mortality	8.8%	10.4%	0.62
Event-Free Survival (EFS)	HR = 0.23 (95%CI= 0.07–0.76)	-	0.015
Relapse Rate	3.9%	5.5%	0.49

Key Findings

Reduced-intensity ATRA+ATO achieves a complete remission rate of 92.3%.
Early mortality rates are comparable between reduced-intensity (8.8%) and intensive (10.4%) therapies.
Event-free survival is significantly better with reduced-intensity induction (HR = 0.23, p = 0.015).
Relapse rates are lower in the reduced-intensity group (3.9% vs 5.5%).
WBC-stratified complete remission rates remain stable with reduced-intensity therapy.

Clinical Implications

The findings support the use of reduced-intensity ATRA+ATO as a first-line therapy for high-risk APL, offering equivalent efficacy with potentially lower toxicity. Clinicians should consider this approach to optimize patient outcomes while minimizing the risk of early mortality.

Conclusion

Reduced-intensity induction therapy with ATRA+ATO is a viable and effective treatment option for high-risk APL, demonstrating comparable remission rates and improved event-free survival compared to intensive chemotherapy.